CClinicalTrials.gg
RecruitingNCT07234292Updated May 4, 2026

Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery

An observational study in Eyelid; Wound, sponsored by Laboratoires Thea. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Laboratoires Thea · Observational

From the registry’s dates

  • Started Oct 2025; still recruiting 11 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis).

The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.

02

Conditions studied

  • Eyelid; Wound

Browse trials for

03

In context

Wounds and Injuries

5,056 studies on the registry are indexed under Wounds and Injuries; 861 are open to participants now.

This study's planned enrollment of 30 is below the median of 135 across 1,597 observational studies indexed under Wounds and Injuries.

Browse Wounds and Injuries studies →

Lead sponsor

Laboratoires Thea is the lead sponsor of 63 studies on the registry; 7 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A total of 30 patients undergoing blepharoplasty or ptosis surgery

Inclusion criteria

  • Age ≥ 18 years old
  • Patients planning a blepharoplasty or a ptosis surgery in at least one eye.
  • Patient affiliated to a health social security system
  • Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end.

Exclusion criteria

Exclusion Criteria:

In terms of population:

  • Pregnant or nursing woman or planning a pregnancy during the study.
  • Patient who had been deprived of their freedom by administrative or legal decision
  • Minor patient.
  • Major patient who is under guardianship or who is not able to express his non opposition.
  • Patient suspected to be non-compliant according to the investigator's judgment.
  • Patient enrolled in another clinical trial or which exclusion period is not over.

In terms of associated pathology

  • Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk.
  • Patient suffering from a severe or progressive disease.
  • Patient with known or suspected hypersensitivity to one of the components of the product.

Related to previous or ongoing treatment

  • Patient undergoing a topical treatment on the test area or a systemic treatment.
  • Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation.
  • Patient under immunosuppressive therapy
  • Patient under bisphosphonate therapy
  • Patient having Type 1 diabetes
  • Patient having atopic or eczema skin

In terms of lifestyle

  • Intensive exposure to sunlight or UV-rays foreseen during the study.
  • Patient planning to change her/his life habits during the study.
  • Patient with an excessive consumption of alcohol and/or tobacco defined as:
  • an excessive consumption of alcohol: Drinking more than
  • 4 units a day for adult men and more than 2 units a day for adult women,
  • an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group receiving Blephaderm

    Other: Cosmetic: Blephaderm

Interventions

  • OtherCosmetic: Blephaderm

    Preservative free eyelid cream: Aqua (water), oleyl erucate, trehalose, sodium acrylates copolymer, lecithin, Ophiopogon japonicus root extract, hydrolyzed hyaluronic acid, maltodextrin, tocopherol, sodium hydroxide, phytic acid, Glycine soja (soybean) oil, Helianthus annuus seed oil.

06

What researchers measure

Primary outcomes

  1. global satisfaction of the patient on eyelid comfort after 3 months of Bllephaderm® use, assessed at M4, using a VAS from 0 (unsatisfied) to 10 (very satisfied).

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • Pierre-Vincent Jacomet Private Practice
    Paris, France
    • Pierre-Vincent Jacomet, Dr. · Contact
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07234292
Lead sponsor
Laboratoires Thea
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Oct 30, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
May 4, 2026

Study contacts

Medical Affairs Director
Contact
florence.noirt@theapharma.com
+33 4 73 98 14 36

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion